Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT02447900 Completed - Clinical trials for Non-Small Cell Lung Cancer

Marker Guided Breathhold Radiotherapy in NSCLC

Start date: July 2014
Phase: Phase 1
Study type: Interventional

Proof of concept study evaluating safety and performance of a gel marker (BioXmark) used for image guidance in deep inspiration breathhold radiotherapy (DIBH IGRT) in patients with locally advanced non-small cell lung cancer (NSCLC)

NCT ID: NCT02445924 Completed - Clinical trials for Non-small Cell Lung Cancer

Micro RNA Genetic Signature in NSCLC Egyptian Patients

Start date: May 2015
Phase: N/A
Study type: Observational

This study will be carried out on 40 subjects at Chest department Tanta university hospital The subjects will be classified into three groups: - Group I: will include ten non smoker volunteers (control group I). - GroupII: will include ten smoker volunteers (control groupII). - Group III: will include twenty NSCLC patients confirmed by pathological examination of bronchoalveolar examination (BAL), brush and/or biopsy.

NCT ID: NCT02445183 Completed - Lung Cancer Clinical Trials

COPDGene/Lung Cancer Center Database

Start date: December 2013
Phase:
Study type: Observational [Patient Registry]

The COPDGene® / Lung Cancer Database Study is a nested case-control study. This study is an ancillary study to COPDGene® Phase 1 and Phase 2. Lung cancer cases, which have been reported by COPDGene® subjects since the time of COPDGene® study enrollment, will be retrospectively verified with additional medical data collection pertaining to lung cancer. Additional 'control' subjects will also be identified and verified as a 'no lung cancer controls'. Data previously collected through the COPDGene® Study, including QCT results and clinical results (medication use, rate of acute exacerbations of COPD, etc) will be used as variables for analysis.

NCT ID: NCT02443324 Completed - Clinical trials for Non-small Cell Lung Cancer

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Start date: July 29, 2015
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), transitional cell carcinoma of the urothelium, or biliary tract cancer (BTC).

NCT ID: NCT02439450 Completed - Clinical trials for Non-small Cell Lung Cancer

A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

Start date: April 15, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study will test whether vaccination with viagenpumatucel-L combined with strategies to modulate the immune response is safe for patients with non-small cell lung adenocarcinoma or squamous cell carcinoma for incurable or metastatic disease.

NCT ID: NCT02437136 Completed - Clinical trials for Non-Small Cell Lung Cancer

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

Start date: July 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

NCT ID: NCT02434081 Completed - Clinical trials for Non-small Cell Lung Cancer Stage III

NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma

NICOLAS
Start date: November 25, 2015
Phase: Phase 2
Study type: Interventional

The aim of the study is to investigate the tolerability (how severe the side effects are) and the efficacy (how well the treatment works) when nivolumab is added to the current standard treatment (chemotherapy and radiotherapy) given to patients with advanced NSCLC.

NCT ID: NCT02430753 Completed - Clinical trials for Lung Neoplasms Accompanied by Respiratory Function Insufficiency

Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency

IRE
Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Lung Neoplasms accompanied by Respiratory Function Insufficiency.

NCT ID: NCT02430597 Completed - Clinical trials for Hilus Pulmonary Neoplasms

Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms

IRE
Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for Hilus Pumonis Neoplasms.

NCT ID: NCT02429843 Completed - Lung Cancer Clinical Trials

A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Start date: November 2, 2015
Phase: Phase 1
Study type: Interventional

This is a single center, open-label, nonrandomized, phase 1b study of TRC105 in combination with standard dose treatment in patients with stage IV non-squamous non-small cell lung cancer.